LifeCycle Pharma A/S to Host Conference Call Announcing Interim Results Q1 2008

Investor Service Announcement no. 3/2008

								        		Hørsholm, Denmark, May 8, 2008


LifeCycle Pharma A/S to Host Conference Call Announcing Interim Results Q1 2008

LifeCycle Pharma A/S (OMX: LCP) will announce interim results for the first
quarter of 2008 which ended March 31, 2008, after the close of OMX Nordic
Exchange Copenhagen, the Danish financial market, on Wednesday, May 14, 2008.
The Executive Management of the company will host an accompanying conference
call to discuss the financial results on Wednesday, May 14, 2008, at 18:00 CET
(Denmark); 17:00 GMT (London); 12:00 a.m. ET (New York); 9:00 a.m. PT (San
Francisco). 

To access the live conference call, please dial one of the following numbers: 
1 866 966 5335 (US)
+44 2030 032 666 (UK)
+45 8088 8649 (DK) 

An audio replay of the conference call will be available on www.lcpharma.com
from 19:00 CET (Denmark); 18:00 GMT (London); 01:00 p.m. ET (New York); 10:00
a.m. PT (San Francisco) on Thursday, May 15, 2008, through Thursday, May 22,
2008, by dialing (UK) +44 2081 961 998, and entering access code 8403 264#. 

About LifeCycle Pharma A/S (“LCP”) 
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, FenoglideTM, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). For further information, please visit www.lcpharma.com. 

For further information please contact:
LifeCycle Pharma A/S
Hans Christian Teisen
Executive Vice President and CFO
+45 2030 6985
HCT@lcpharma.com